Cite
Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011).
MLA
Enama, Mary E., et al. “Phase I Randomized Clinical Trial of VRC DNA and RAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011).” PLoS ONE, vol. 9, no. 3, Mar. 2014, pp. 1–11. EBSCOhost, https://doi.org/10.1371/journal.pone.0091366.
APA
Enama, M. E., Ledgerwood, J. E., Novik, L., Nason, M. C., Gordon, I. J., Holman, L., Bailer, R. T., Roederer, M., Koup, R. A., Mascola, J. R., Nabel, G. J., & Graham, B. S. (2014). Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011). PLoS ONE, 9(3), 1–11. https://doi.org/10.1371/journal.pone.0091366
Chicago
Enama, Mary E., Julie E. Ledgerwood, Laura Novik, Martha C. Nason, Ingelise J. Gordon, LaSonji Holman, Robert T. Bailer, et al. 2014. “Phase I Randomized Clinical Trial of VRC DNA and RAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011).” PLoS ONE 9 (3): 1–11. doi:10.1371/journal.pone.0091366.